Elevance Health Inc (ELV) is gearing up for another turning point as it hit the volume of 1.13 million

Elevance Health Inc (NYSE: ELV) kicked off on Tuesday, up 1.38% from the previous trading day, before settling in for the closing price of $500.09. Over the past 52 weeks, ELV has traded in a range of $412.00-$521.18.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 13.24%. While this was happening, its average annual earnings per share was recorded 12.08%. With a float of $231.50 million, this company’s outstanding shares have now reached $233.07 million.

Considering the fact that the conglomerate employs 104900 people, you should pay attention to its efficiency factor.

Elevance Health Inc (ELV) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Healthcare Plans Industry. The insider ownership of Elevance Health Inc is 0.50%, while institutional ownership is 91.70%. The most recent insider transaction that took place on Mar 08 ’24, was worth 1,217,119. In this transaction EVP & President, Commercial of this company sold 2,432 shares at a rate of $500.46, taking the stock ownership to the 15,840 shares. Before that another transaction happened on Mar 06 ’24, when Company’s CAO & Controller sold 916 for $504.58, making the entire transaction worth $462,195. This insider now owns 1,764 shares in total.

Elevance Health Inc (ELV) Earnings and Forecasts

According to the Wall Street analysts, stocks earnings will be around 12.08% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.81% during the next five years compared to 12.18% growth over the previous five years of trading.

Elevance Health Inc (NYSE: ELV) Trading Performance Indicators

Take a look at Elevance Health Inc’s (ELV) current performance indicators. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.69. Likewise, its price to free cash flow for the trailing twelve months is 17.44.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 25.17, a number that is poised to hit 10.52 in the next quarter and is forecasted to reach 41.56 in one year’s time.

Technical Analysis of Elevance Health Inc (ELV)

Compared to the last year’s volume of 1.03 million, its volume of 1.02 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 36.60%. Additionally, its Average True Range was 8.45.

During the past 100 days, Elevance Health Inc’s (ELV) raw stochastic average was set at 80.31%, which indicates a significant increase from 48.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.28% in the past 14 days, which was higher than the 15.72% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $506.99, while its 200-day Moving Average is $472.77. Nevertheless, the first resistance level for the watch stands at $512.77 in the near term. At $518.56, the stock is likely to face the second major resistance level. The third major resistance level sits at $523.12. If the price goes on to break the first support level at $502.42, it is likely to go to the next support level at $497.86. Should the price break the second support level, the third support level stands at $492.07.

Elevance Health Inc (NYSE: ELV) Key Stats

The company with the Market Capitalisation of 117.96 billion has total of 232,700K Shares Outstanding. Its annual sales at the moment are 171,340 M in contrast with the sum of 5,987 M annual income. Company’s last quarter sales were recorded 42,647 M and last quarter income was 856,000 K.